Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

1 early termination which also counts as a failure

Message Board Public Reply | Private Reply | Keep | Replies (3)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154835
(Total Views: 171)
Posted On: 03/07/2019 7:57:52 PM
Avatar
Posted By: trding
Re: finesand #740
Quote:
1 early termination which also counts as a failure per



Not counted in the "viral failure" group, it is possible to terminate and still have a suppressed viral load.

Quote:
They say they want to enroll additional 200 pts across all 3



Only across the 525 vs 700 group, dose-response study showing the effectiveness without placabo if there is distinguishable results. This is 100 525mg vs 100 700mg, which they have already enrolled most, starting last year. I posted this week here how many at least they currently have at 700, some were enrolled in February.

Quote:
Why not simply enroll them to 700mg only?



This 200 additional pts above 300 started last year, not now, 525 vs 700 random in dose-response study. I posted here early the fda guidebook talking about this. Also 525 is still viable. Most failures happen early, not randomly throughout the trial, so they are going to add a 5x half-life overlap bring leronlimab to steady-state before stopping haart. Also switch to induction/maintenance, which will change success/failure.

Quote:

Safety wise, we had 30 SAE incidents in total of 387 pts or 7.75%, where it is unknown whether these were definitely or probably related to PRO 140.

This is probably OK, but have no details about the nature of the SAEs yet.




It says: "None of the reported SAEs were definitely or probably related to PRO140(leronlimab)"


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us